ArticleKidney research and clinical practice2021
Intestinal microbiota and kidney diseases.
Article in Kidney research and clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review.Current diabetes reviews · 2026Pooled it
- Gut microbiome dynamics in acute infectious diarrhea: A conceptual framework from acute dysbiosis toward precision restoration (Review).Experimental and therapeutic medicine · 2026Review
- Mesoamerican nephropathy: A silent epidemic at the nexus of climate, labor, and health.AIMS public health · 2026Article
- Gut Microbiota Dysbiosis and Metabolite Imbalance Mediate Diabetic Kidney Disease Inflammation: Mechanisms and Intervention Strategies Targeting Gut-Kidney Axis and NF-κB/NLRP3 Pathways.Journal of inflammation research · 2026Review
- Understanding the intricate interactions between microbiota and host.World journal of experimental medicine · 2025Review
- Probiotics in the prevention and treatment of calcium oxalate kidney stones: mechanisms and therapeutic potential.Frontiers in microbiology · 2025Review
- How is the human microbiome linked to kidney stones?Frontiers in cellular and infection microbiology · 2025Review
- Indoxyl sulfate induces apoptotic cell death by inhibiting glycolysis in human astrocytes.Kidney research and clinical practice · 2024Article
- Pathophysiology and Main Molecular Mechanisms of Urinary Stone Formation and Recurrence.International journal of molecular sciences · 2024Review
- Pharmacologic therapeutics in sarcopenia with chronic kidney disease.Kidney research and clinical practice · 2024Article
- Gut Microbiota Modulation and Its Implications on Neuropathic Pain: A Comprehensive Literature Review.Pain and therapy · 2024Review
- Research progress of traditional Chinese medicine on the treatment of diarrhea by regulating intestinal microbiota and its metabolites based on renal-intestinal axis.Frontiers in cellular and infection microbiology · 2024Review
- Review
- Early gut microbiological changes and metabolomic changes in patients with sepsis: a preliminary study.International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
- The Gut-Peritoneum Axis in Peritoneal Dialysis and Peritoneal Fibrosis.Kidney medicine · 2023Review
- Sulfur-Containing Amino Acids, Hydrogen Sulfide, and Sulfur Compounds on Kidney Health and Disease.Metabolites · 2023Review
- Article
- Role of the Gut Microbiota in Children with Kidney Disease.Children (Basel, Switzerland) · 2023Article
- Gut Microbiota Alterations and Primary Glomerulonephritis in Children: A Review.International journal of molecular sciences · 2022Review
- Role of T cells in ischemic acute kidney injury and repair.The Korean journal of internal medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Large microbial communities reside in the gut as an endogenous organ and interact with the host physiology through symbiotic relationships, affecting health. Recent advances in high-throughput sequencing techniques have made it possible to better understand these complex microbial communities and their effects on hosts. Animal and clinical studies have provided considerable evidence to show that the microbiota plays an important role in chronic kidney disease, acute kidney injury, nephrolithiasis, and kidney transplantation by altering the functions of the intestinal barrier, regulating local and systemic inflammation, controlling production of metabolic components, and affecting immune responses. Although the exact mechanism underlying the microbial shift and its impact on disease progression remains uncertain, the kidney-gut interaction clearly plays a significant role in onset and progression of kidney disease and, therefore, holds promise as a therapeutic target. Here, we review recent literature pertaining to the bidirectional relationship between microbes and humans in various kidney diseases and discuss the future direction of microbial research in nephrology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.